Form 4: Fairmount Funds Manager Granted Damora Therapeutics Options

Peter Harwin, a director and manager of Fairmount Funds, received stock options for 37,313 shares of Damora Therapeutics common stock.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest V L.P., Tomas Kiselak, and Peter Harwin are reporting persons for this transaction.
• Peter Harwin, who serves as a director and is associated with a 10% owner, was granted a stock option to purchase 37,313 shares of Damora Therapeutics, Inc. common stock.
• The exercise price for these stock options is $23.05 per share.
• The transaction date for the option grant was March 23, 2026.
• The option is scheduled to vest in equal monthly installments through March 23, 2029, contingent upon Mr. Harwin's continued service to the Issuer.
• The expiration date for the stock option is March 23, 2036.
• Mr. Harwin holds this option for the benefit of one or more investment vehicles managed by Fairmount, and he is obligated to transfer any net cash or stock received from the option to Fairmount for the benefit of these funds.
• Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.
• Fairmount, Fund II, and Co-Invest may be considered directors by deputization due to Peter Harwin's role on the board of directors and as a manager of Fairmount.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the grant of stock options to a director and representative of a significant investor aligns their incentives with the company's long-term success and demonstrates continued commitment.

Positives

• A director and representative of a significant investor, Peter Harwin, received a substantial stock option grant, which aligns his long-term financial interests with those of Damora Therapeutics' shareholders.
• The multi-year vesting schedule through March 2029 incentivizes Mr. Harwin's continued service and commitment to the company's strategic direction and performance.

Risks

• The ultimate value of the stock option is directly dependent on the future market performance of Damora Therapeutics' common stock.
• The vesting of the stock option is conditional on Peter Harwin's continued service to the Issuer, introducing a dependency on his ongoing involvement.

Future Outlook

The option's vesting schedule through March 23, 2029, implies an expectation of Peter Harwin's continued service to Damora Therapeutics, aligning his long-term incentives with the company's performance.

Management Comments

• "This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."
• "Fairmount Funds Management LLC ('Fairmount') is the investment manager for Fairmount Healthcare Fund II LP ('Fund II') and Fairmount Healthcare Co-Invest V L.P. ('Co-Invest'). Peter Harwin and Tomas Kiselak are the managers of Fairmount."
• "Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a 'Fairmount Fund'). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund."
• "Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."
• "Fairmount, Fund II and Co-Invest may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount."

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into equity movements by company officers, directors, and significant shareholders. The grant of stock options to a director and representative of a major investment fund is a common practice to align management and investor interests with the company's long-term performance.

Corporate Governance

Related Party Transactions

• The grant of stock options to Peter Harwin, a director of Damora Therapeutics and a manager of Fairmount Funds Management LLC (a 10% owner of the Issuer), constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The option grant aligns the interests of a significant investor and director with long-term shareholder value, potentially fostering more committed oversight and strategic direction.
• Management/Employees: Peter Harwin's continued service is incentivized, which could contribute to stability and strategic continuity within the company.

Next Steps

• Peter Harwin's continued service to Damora Therapeutics is required for the stock option to vest in equal monthly installments through March 23, 2029.

Key Dates

Keywords

Damora Therapeutics, DMRA, Fairmount Funds Management, Peter Harwin, Tomas Kiselak, Stock Option, Insider Transaction, Form 4, Equity Grant, Director Compensation, 10% Owner